The company, led by highly experienced immuno-oncology scientists, utilizes various technology platforms to develop novel therapeutic bi-specific and multi-specific antibodies, as well as antibody-drug conjugates. Their goal is to create world-class treatments that target cancer cells and improve patient outcomes.